Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis.


Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 14 06 2019
revised: 24 07 2019
accepted: 02 08 2019
pubmed: 11 8 2019
medline: 25 2 2021
entrez: 11 8 2019
Statut: ppublish

Résumé

The disease burden of pyoderma gangrenosum (PG) is poorly understood. To determine standardized overall and age-, sex-, and race-specific prevalence estimates for PG among adults in the United States. Cross-sectional analysis of 1971 patients with PG identified using electronic health records data from a diverse population-based sample of more than 58 million patients. The age- and sex-standardized prevalence of PG among the study population was 0.0058%, or 5.8 PG cases (95% confidence interval [CI], 5.6-6.1) per 100,000 adults. Adjusted prevalence was nearly twice as high among women (7.1 cases [95% CI, 6.7-7.5] per 100,000) than men (4.4 cases [95% CI, 4.0-4.7] per 100,000). Patients between the ages of 70 and 79 years had the highest standardized prevalence (9.8 cases [95% CI, 8.8-10.9] per 100,000), with patients aged ≥50 years representing nearly 70% of all PG cases. Standardized prevalence was similar among white and African American patients. The female-to-male ratio of PG was >1.8 across all age groups. Analysis of electronic health records data may result in misclassification bias. PG is a rare disease that most commonly affects women and those aged ≥50 years.

Sections du résumé

BACKGROUND BACKGROUND
The disease burden of pyoderma gangrenosum (PG) is poorly understood.
OBJECTIVE OBJECTIVE
To determine standardized overall and age-, sex-, and race-specific prevalence estimates for PG among adults in the United States.
METHODS METHODS
Cross-sectional analysis of 1971 patients with PG identified using electronic health records data from a diverse population-based sample of more than 58 million patients.
RESULTS RESULTS
The age- and sex-standardized prevalence of PG among the study population was 0.0058%, or 5.8 PG cases (95% confidence interval [CI], 5.6-6.1) per 100,000 adults. Adjusted prevalence was nearly twice as high among women (7.1 cases [95% CI, 6.7-7.5] per 100,000) than men (4.4 cases [95% CI, 4.0-4.7] per 100,000). Patients between the ages of 70 and 79 years had the highest standardized prevalence (9.8 cases [95% CI, 8.8-10.9] per 100,000), with patients aged ≥50 years representing nearly 70% of all PG cases. Standardized prevalence was similar among white and African American patients. The female-to-male ratio of PG was >1.8 across all age groups.
LIMITATIONS CONCLUSIONS
Analysis of electronic health records data may result in misclassification bias.
CONCLUSION CONCLUSIONS
PG is a rare disease that most commonly affects women and those aged ≥50 years.

Identifiants

pubmed: 31400451
pii: S0190-9622(19)32494-6
doi: 10.1016/j.jaad.2019.08.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-429

Informations de copyright

Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Amy Xu (A)

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Amrita Balgobind (A)

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Andrew Strunk (A)

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Amit Garg (A)

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Allireza Alloo (A)

Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. Electronic address: aalloo@northwell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH